10-Q: AdaptHealth Q3 2025: Revenue Up, Debt Down, Legal Settlement

AdaptHealth Corp. reported a 1.8% increase in Q3 2025 net revenue to $820.3 million, alongside significant debt reduction and an agreement in principle to settle a class action lawsuit.

Summary

• Net revenue for the three months ended September 30, 2025, increased by 1.8% to $820.3 million, compared to $805.9 million in the prior year period.
• Net revenue for the nine months ended September 30, 2025, slightly decreased by 0.2% to $2.40 billion, compared to $2.40 billion in the prior year period.
• Organic revenue growth was 5.1% for the three months and 1.8% for the nine months ended September 30, 2025.
• Net income attributable to AdaptHealth Corp. for the three months ended September 30, 2025, increased by 7.2% to $24.5 million, up from $22.9 million in Q3 2024.
• Net income attributable to AdaptHealth Corp. for the nine months ended September 30, 2025, decreased by 20.4% to $32.0 million, down from $40.2 million in YTD 2024.
• Adjusted EBITDA for the three months ended September 30, 2025, increased by 3.5% to $170.1 million, with an Adjusted EBITDA Margin of 20.7%.
• Adjusted EBITDA for the nine months ended September 30, 2025, decreased by 7.1% to $453.5 million, with an Adjusted EBITDA Margin of 18.9%.
• Free cash flow decreased by 21.2% to $66.8 million for the three months and by 13.8% to $140.1 million for the nine months ended September 30, 2025.
• The company made voluntary repayments of $212.8 million on its 2024 Term Loan during the nine months ended September 30, 2025, reducing long-term debt.
• An agreement in principle was reached on October 24, 2025, to settle the Allegheny County Consolidated Class Action lawsuit, with the cash payment primarily funded by insurance carriers.
• The U.S. Attorney's Office for the Southern District of New York informed the company in August 2025 that it does not presently intend to pursue False Claims Act (FCA) claims regarding ventilators.
• A material weakness in internal control over financial reporting related to inventory valuation continues to exist as of September 30, 2025, with remediation efforts ongoing.

Sentiment

Score: 5

Explanation: While Q3 showed some positive growth in revenue and net income, the year-to-date performance is weaker, with declines in overall revenue, net income, and Adjusted EBITDA. Free cash flow also decreased significantly. The ongoing material weakness in internal controls and multiple active FCA investigations, despite one closure, add uncertainty. The debt reduction is a positive, but the substantial drop in working capital is a concern, leading to a neutral-to-slightly-negative sentiment.

Positives

• Net revenue increased by 1.8% to $820.3 million for the three months ended September 30, 2025, compared to the prior year.
• Organic revenue growth was strong at 5.1% for the three months and 1.8% for the nine months ended September 30, 2025.
• Net income attributable to AdaptHealth Corp. increased by 7.2% to $24.5 million for the three months ended September 30, 2025.
• Adjusted EBITDA increased by 3.5% to $170.1 million for the three months ended September 30, 2025, with an improved margin of 20.7%.
• Significant voluntary repayments of $212.8 million were made on the 2024 Term Loan during the nine months ended September 30, 2025, reducing overall debt.
• The U.S. Attorney's Office for the Southern District of New York does not presently intend to pursue FCA claims regarding ventilators, closing one investigation.
• An agreement in principle was reached to settle the Allegheny County Consolidated Class Action lawsuit, with insurance carriers expected to primarily fund the cash payment.
• The One Big Beautiful Bill Act (OBBBA) signed on July 4, 2025, reduced the company's 2025 estimated cash income tax liability by $32.7 million, resulting in a current income tax receivable.

Negatives

• Net revenue for the nine months ended September 30, 2025, slightly decreased by 0.2% to $2.40 billion.
• Net income attributable to AdaptHealth Corp. for the nine months ended September 30, 2025, decreased significantly by 20.4% to $32.0 million.
• Adjusted EBITDA for the nine months ended September 30, 2025, decreased by 7.1% to $453.5 million, with the Adjusted EBITDA Margin declining to 18.9%.
• Free cash flow decreased by 21.2% to $66.8 million for the three months and by 13.8% to $140.1 million for the nine months ended September 30, 2025, primarily due to increased purchases of patient medical equipment.
• Working capital significantly decreased by 71.3% from $188.8 million as of December 31, 2024, to $54.1 million as of September 30, 2025.
• A material weakness in internal control over financial reporting related to the determination of excess or obsolete medical equipment and other inventory balances continues to exist.
• Two other civil investigative demands from U.S. Attorney's Offices (District of South Carolina and Eastern District of Pennsylvania) regarding alleged false claims are ongoing, with potential material adverse effects currently undeterminable.
• The Diabetes Health segment experienced a 2.1% decrease in net revenue for the nine months ended September 30, 2025, and a 43.2% decrease in Adjusted EBITDA, primarily due to a shift in payor mix from commercial insurance to government payors.

Risks

• Inflationary pressures and higher costs for materials, labor, and transportation could impact demand, costs, and margins.
• Fluctuations in the U.S. and/or global stock markets could adversely affect the business.
• Changes in applicable laws or regulations, particularly in healthcare, could impact operations and financial performance.
• Competition and the ability to grow and manage profitable growth are ongoing challenges.
• The federal government shutdown, effective October 1, 2025, may cause delays in Medicare and Medicaid payments.
• A U.S. Department of Commerce investigation under Section 232 into imports of personal protective equipment, medical consumables, and medical equipment could lead to additional tariffs, materially affecting the business.
• Ongoing civil investigative demands from the U.S. Attorney's Office for the District of South Carolina (regarding humidifiers with CPAP) and the Eastern District of Pennsylvania (regarding respiratory devices) could result in material adverse effects.
• The shareholder derivative complaint (Wu Derivative Action) and the books and records inspection action (Myers Section 220 Action) are ongoing, with uncertain outcomes.
• The company has a significant amount of goodwill on its balance sheet, which is subject to annual impairment assessment and could result in material non-cash impairment charges.
• The complexity of third-party billing arrangements and laws governing Medicare and Medicaid may lead to adjustments to recorded revenues and affect net realizable values of accounts receivable.
• The company's ability to obtain additional equity or debt financing for growth, particularly acquisitions, could be impacted by disruptions in capital markets.

Future Outlook

The company expects to receive federal and state corporate income tax refunds in 2026 due to the One Big Beautiful Bill Act (OBBBA). It believes that its expected operating cash flows, together with existing cash and amounts available under its credit agreement, will be sufficient to fund operations and growth strategies for at least the next twelve months. However, it may seek additional equity or debt financing for acquisitions and acknowledges that economic conditions could disrupt capital markets, making financing more difficult or expensive.

Management Comments

• Management believes organic revenue is meaningful to investors as it provides appropriate visibility into how AdaptHealth changes organically—that is, within its existing operations using its own resources.
• Management believes any liability that may ultimately result from resolution of such loss contingencies will not have a material adverse effect on the company’s financial condition or results of operations, though this assessment may change.
• Notwithstanding the identified material weakness, management, including our Chief Executive Officer and Chief Financial Officer, believes the interim consolidated financial statements included in this Quarterly Report on Form 10-Q fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. GAAP.

Industry Context

The company operates in the patient-centered, healthcare-at-home solutions market, providing home medical equipment and services across four segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home. It notes experiencing inflationary pressures on costs for materials, labor, and transportation, which it is mitigating through purchasing power and technology. The business is subject to seasonality, with lower revenue and cash flow in the early part of the year due to patient deductibles and insurance changes. The U.S. Department of Commerce's Section 232 investigation into medical equipment imports poses a potential risk of additional tariffs, which could impact the industry.

Legal Proceedings

• U.S. Attorney's Office for the Southern District of New York (SDNY) civil investigative demand regarding false claims for ventilators (Jan 1, 2015 present): SDNY informed in August 2025 no present intent to pursue FCA claims.
• Allegheny County Consolidated Class Action (shareholder class action regarding billing practices for diabetes products and compliance programs, Aug 4, 2020 Nov 7, 2023): Agreement in principle to settle reached October 24, 2025, primarily funded by insurance, subject to court approval.
• Weiding Wu Shareholder Derivative Action (related to Allegheny County allegations): Stayed pending final resolution of the Allegheny County Consolidated Class Action.
• Blake T. Myers Section 220 Action (seeking to inspect books and records related to Allegheny County allegations): Company completed production on September 26, 2025; action stayed pending further requests.
• U.S. Attorney's Office for the District of South Carolina civil investigative demand regarding false claims for humidifiers integrated with CPAP devices (Jan 1, 2017 present): Ongoing, cannot determine material adverse effect.
• U.S. Attorney's Office for the Eastern District of Pennsylvania civil investigative demand regarding false claims for respiratory devices and related supplies (Jan 1, 2018 present): Ongoing, cannot determine material adverse effect.

Related Party Transactions

• The company owns an equity interest in a vendor that provides automated order intake software; expense related to this vendor was $5.2 million for Q3 2025 and $14.1 million for YTD 2025.
• A director of the company serves on the board of directors of a third-party payor; net revenue from this payor was approximately 1.0% of consolidated net revenue for Q3 and YTD 2025.
• A director of the company is an employee of a beneficial owner (>5% Common Stock) who is also a minority shareholder of a medical equipment and supplies vendor; payments to this vendor were approximately $14.5 million for Q3 2025 and $53.4 million for YTD 2025.

Stakeholder Impact

• Shareholders: Mixed financial results (Q3 up, YTD down) provide mixed signals. The class action settlement, primarily insurance-funded, is a positive, but ongoing legal risks and the material weakness in internal controls remain concerns.
• Employees: Labor costs increased due to merit and inflationary increases, as well as benefits costs.
• Customers/Patients: Increased patient census in Sleep Health and Respiratory Health segments indicates continued service provision.
• Suppliers: Inflationary pressures on the cost of products and supplies are noted, with the company leveraging its purchasing power in negotiations.
• Creditors: Significant voluntary debt repayments of $212.8 million on the term loan demonstrate commitment to debt reduction, and the company remains in compliance with debt covenants.

Next Steps

• Negotiate and file a formal settlement agreement and preliminary approval motion for the Allegheny County Consolidated Class Action by November 24, 2025.
• Myers and the company are continuing to confer regarding the Section 220 action, with a subsequent update to the Court on December 3, 2025.
• Continue remediation efforts for the material weakness in internal control over financial reporting, including the remaining implementation program of a perpetual inventory system.
• Monitor developments regarding the SEC's climate disclosure rules, including whether they will become effective.
• Monitor the U.S. Department of Commerce's Section 232 investigation into medical equipment imports for potential tariffs.
• Expect to receive federal and state corporate income tax refunds in 2026 due to the One Big Beautiful Bill Act (OBBBA).

Key Dates

Recommendation

While AdaptHealth demonstrated positive Q3 revenue and net income growth, the year-to-date performance shows a slight revenue decline and a significant drop in net income and Adjusted EBITDA. The substantial reduction in working capital and free cash flow raises liquidity concerns. The agreement in principle to settle a major class action lawsuit, largely covered by insurance, is a positive development, but the company still faces multiple ongoing FCA investigations and a persistent material weakness in internal controls over inventory valuation. The debt reduction is favorable, but overall, the mixed financial picture and lingering operational/legal uncertainties suggest a 'Hold' position until there is clearer evidence of sustained operational improvement and resolution of control weaknesses and investigations.

Keywords

Home medical equipment, HME, Sleep Health, Respiratory Health, Diabetes Health, Wellness at Home, CPAP, Continuous Glucose Monitors, Insulin Pumps, SEC filing, 10-Q, Financial results, Healthcare-at-home, Medical supplies, AdaptHealth, Adjusted EBITDA, Free Cash Flow, Debt reduction, Legal settlement, Internal controls, FCA investigation